Potassium channel Inhibitors
1 drugsAbout Potassium channel
Potassium channels are transmembrane proteins regulating cellular excitability and ion homeostasis by selectively conducting potassium ions. They influence nerve impulse transmission, muscle contraction, and hormone secretion.
Potassium channels are potential therapeutic targets, but currently, there is no genetic evidence data available linking them to specific diseases in this dataset.
FIRDAPSE is the only FDA-approved drug targeting potassium channels, developed by CATALYST PHARMS as a small molecule therapy.
Top Potassium channel Drugs
CATALYST PHARMS is the only company with an approved potassium channel-targeting drug.
Low competition suggests opportunity, but also highlights potential challenges in the therapeutic area.
Potassium channel Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Potassium channel, using small molecule modality.
Explore novel modalities like antibodies or gene therapies to differentiate from existing treatments.
Potassium channel Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Potassium channel. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 3 | 2 | 1 | 0 | 67% |
| Phase 3 | 5 | 4 | 1 | 0 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Potassium channel Drug Approval Timeline (2018 - 2018)
FIRDAPSE was both the first and most recently approved drug, in 2018.
Recent approval but lack of subsequent entries indicates potential saturation or high entry barriers.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Potassium channel. A trial counts if an approved drug acting on Potassium channel is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.